Indication: Liposarcoma
Title: SEAL: Selinexor in Advanced Liposarcoma 
Drug: selinexor

SEAL is a Phase 3 randomized, multicenter, double-blind, placebo-controlled study evaluating selinexor in patients with advanced unresectable dedifferentiated liposarcoma

Please visit clinicaltrials.gov for more information about this study

This trial is for selinexor.

Rights

Drug: selinexor

PreclinicalPhase IPhase IIPhase III
Preclinical
Phase I
Phase II
Phase III